本文へ移動
cccskills
無料GitHub で公開

enda-dhea-trial-women-symptoms

Suggests a trial of dehydroepiandrosterone (DHEA) replacement in women with primary adrenal insufficiency (PAI) who report low libido, depressive symptoms, and/or low energy levels despite otherwise optimized glucocorticoid and mineralocorticoid replacement. Consider when a woman with PAI presents with persistent low libido, depressive symptoms, and/or low energy levels after glucocorticoid and mineralocorticoid doses have been titrated to clinical targets.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.8 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Trial DHEA Replacement in Women with PAI and Specific Symptoms

STEP 1 — Gather Information

Confirm PAI diagnosis, review current glucocorticoid (e.g., hydrocortisone 15–25 mg/day) and mineralocorticoid (fludrocortisone 50–100 µg/day) doses, assess for clinical signs of over- or under-replacement (weight, BP, electrolytes), and document presence of low libido, depressive symptoms, and/or low energy levels.

STEP 2 — Rule In / Rule Out

Determine whether symptoms persist despite optimized steroid replacement; if yes, proceed to DHEA trial consideration, otherwise evaluate for other causes of fatigue or low libido (e.g., thyroid dysfunction, depression, anemia).

STEP 3 — Classify or Stratify

Classify the patient as a candidate for a DHEA replacement trial if she is a woman with PAI, has low libido, depressive symptoms, and/or low energy levels, and is on otherwise optimized glucocorticoid and mineralocorticoid therapy; proceed to step 4 to initiate the trial.

STEP 4 — Decide

Initiate a trial of DHEA 25–50 mg orally each morning, measure morning serum DHEAS before each dose aiming for the mid-normal range, and schedule clinical reassessment of libido, mood, and energy after 6 months; if sustained benefit is reported, continue therapy, otherwise discontinue DHEA.

Clinical Guardrails / Mimics / Pitfalls

Do not use DHEA as first-line therapy before optimizing glucocorticoid and mineralocorticoid replacement; avoid in men, pregnancy, or hormone-sensitive malignancies; monitor for androgenic side effects (acne, hirsutism, voice changes); do not rely solely on DHEAS levels without clinical response; DHEA is not routinely recommended due to insufficient evidence for broad use.

Concrete Clinical Example

A 48-year-old woman with autoimmune PAI on hydrocortisone 20 mg daily and fludrocortisone 100 µg daily reports persistent low libido and fatigue despite stable weight, normal BP, and normal electrolytes; after confirming optimized replacement, a trial of DHEA 25 mg each morning is started; at 6‑month follow‑up she notes improved energy and libido, DHEAS is mid‑normal, and therapy is continued.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する